Publication | Open Access

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

VaccinationVaccine SafetyVaccine DevelopmentImmunologyInterim ResultsVaccine EfficacyInactivated Sars-cov-2 VaccineMedicinePhase 3Covid-19